St. Elisabeth Hospital Tilburg
- Address
- Hilvarenbeekseweg 60, 5022 GC Tilburg, The Netherlands
Cardiovascular Diseases and Acute Myocardial Infarction
At St. Elisabeth Hospital Tilburg, cardiac research includes studies focused on acute myocardial infarction and prevention of recurrent events. The trials are designed to assess new treatment strategies that may help patients respond faster when symptoms appear and improve outcomes after a heart attack.
- Evaluating a self-administered therapy for suspected acute myocardial infarction
- Improving early treatment options for patients at risk of recurrent cardiac events
- Studying better ways to reduce complications and strengthen emergency care in cardiology
These studies reflect a strong interest in urgent cardiovascular care and in testing approaches that may make treatment more effective for people with serious heart disease.
Digestive System Diseases and Inflammatory Bowel Disease
Research in digestive system diseases centers on Crohn's disease and ulcerative colitis, with trials aimed at improving symptom control and long-term disease management. The main goal is to evaluate new therapies that may offer better relief for patients with moderate to severe inflammatory bowel disease.
- Testing treatments for Crohn's disease after prior therapy has not worked well
- Assessing options for ulcerative colitis to improve endoscopic healing and symptom remission
- Exploring safer and more effective approaches for chronic intestinal inflammation
These trials support ongoing efforts to improve quality of life for people living with persistent gastrointestinal inflammation.
Neoplasms and Hemic and Lymphatic Diseases
The oncology and hematology portfolio at St. Elisabeth Hospital Tilburg includes trials in diffuse large B-cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and advanced lung cancer. The research is centered on testing combination treatments and consolidation strategies that may improve survival and disease control.
- Studying new treatment combinations for diffuse large B-cell lymphoma and high-risk lymphoma subtypes
- Evaluating therapies for chronic lymphocytic leukemia and small lymphocytic lymphoma in relapsed or resistant disease
- Assessing treatment approaches for advanced non-small cell lung cancer with specific molecular features
These studies focus on improving remission rates, delaying progression, and expanding treatment choices in blood cancers and solid tumors.
Female Urogenital Diseases and Pregnancy Complications and Reproductive and Urinary Physiological Phenomena
Clinical research in this area addresses unexplained subfertility and infertility, with an emphasis on helping couples undergoing assisted conception. The trials are intended to determine whether supportive treatments can improve the chance of a successful pregnancy.
- Testing ways to improve live birth rates during intra-uterine insemination
- Studying supportive care for couples with subfertility or infertility
- Evaluating whether added treatment support can make fertility care more effective and cost-conscious
These studies reflect a practical focus on reproductive health outcomes and better support for patients seeking fertility treatment.
Musculoskeletal Diseases and Bacterial Infections and Mycoses
Trials in this field examine prosthetic joint infection, a serious complication affecting patients with joint replacements. The research aims to compare antibiotic strategies and identify treatment approaches that may control infection while preserving recovery and mobility.
- Comparing targeted antibiotic treatment with traditional combination therapy for prosthetic joint infection
- Assessing whether simpler infection treatment can be as effective as standard regimens
- Supporting better management of implant-related bacterial infections
These studies are important for improving care after orthopedic surgery and reducing the burden of persistent joint infections.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 24 therapeutic areas and 15 of 253 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 223 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 33 by active trials.
- 1Merck Sharp & Dohme LLC7active
lock +32 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC11trials
lock +21 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in St. Elisabeth Hospital Tilburg
lock Showing 1 of 118 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 253 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 11 | Unknown | 2015-11-06 | 2026-07-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
